Invivyd Inc 뉴스 - IVVD | 주식 나스닥

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart...

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million...

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging...

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR

CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by...

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Form 8-K - Current report

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Preliminary Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with...

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with...

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

glenn1919 2 일 전

IVVD..........................https://stockcharts.com/h-sc/ui?s=IVVD&p=W&b=5&g=0&id=p86431144783

👍️0

Viewmont 2 주 전

$IVVD WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

The presentation is set to take place at 1:20 PM ET on Wednesday, February 12th. The live webcast link will be available in the investor section of the company's website at https://investors.invivyd.com and will be archived for approximately 90 days following the event.

About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

👍️0

Viewmont 2 주 전

$IVVD On February 3, 2025, the Company issued a press release entitled “Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population.” A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.

👍️0

glenn1919 2 주 전

IVVD..........................https://stockcharts.com/h-sc/ui?s=IVVD&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2 주 전

IVVD......................https://stockcharts.com/h-sc/ui?s=IVVD&p=W&b=5&g=0&id=p86431144783

👍️0

Invest-in-America 2 주 전

IVVD: L.O.L.!!! (That must be TRUMP's ass --- and the backside of his 'MAGNA' hat!!!)

👍️0

B RY 2 주 전

Here's a nice fluffy pillow similar to other companies pr's, lol.>>>

👍️0

B RY 2 주 전

Very true! I'll take an ivvd fda phase 3 talks with an 8k showing stronger financial strength over the fluff pr's other companies put out anyday.

👍️0

Invest-in-America 2 주 전

IVVD: Very-well-stated, Dude!! (And yet every day we see yet another bogus, Pre-Clinical, study in useless Petri Dishes, Test Tubes, or in the ass of MICE!! And worse yet of late, mere "DIGITAL STUDIES" in a cheap Apple Laptop COMPUTER!!!)

👍️0

B RY 2 주 전

Shorting ivvd currently is financial roulette imo.

👍️0

B RY 2 주 전

I like their product being in phase 3 discussions with the fda. Phase 1 means a company is lucky to hear back from the fda. Phase 2 means the product is worth the fda's time to open discussion. Phase 3 means the fda is in serious talks about approving the product and in deep discussion with the company. Phase 4 is the final fda approval process discussions covering any unanswered fda questions and closing dialogue. That being said, I love seeing ivvd in phase 3 talks. Upon fda approval, this company should show profitable within a year or so from where it is now financially. The "emergency use" status will be a mute point with it's product fda approved for sale. I'm looking forward to seeing it's financial position in a couple of years. We have a real winner imo Invest.

👍️0

Invest-in-America 2 주 전

IVVD: This thing had soared HUGELY in just 3-days --- nearly 600%. But now, it's pure guess work. (EVERY company everywhere is now suddenly touting their 'revolutionary', disruptive, all-new, QUANTUM-AI-CUSTOM-TAILORED-HEALTHCARE, routines.)

👍️0

Stockexpertpro 2 주 전

GSIW 1$ Breakout Coming Shorts will have to Buy to Cover

👍️0

B RY 2 주 전

I would love to sell my ivvd and buy below $2, but I seriously doubt it will retrace below $2 for more than a couple of pennies. The upcoming march 28th annual report will be too highly anticipated after monday's 8k. This ivvd ride will most certainly be the most stock fun I've had in a while. I prefer downhill skiing for a good rush, but I think as far as stocks are concerned, ivvd will prove to have a good rush as well. It's 12 month $7.89 price target will come much sooner imo. I still think testing politicians first is a good idea.

👍️0

Invest-in-America 3 주 전

IVVD: Indeed; and Trump already had to do that in his FIRST term, behind getting that first Covid-19 vaccine launched.

👍️0

B RY 3 주 전

"Emergency use Authorization" will prove a huge asset.

👍️0

Invest-in-America 3 주 전

IVVD: I think Trump, Vance, & Musk, et al., are somehow cleverly-affiliated with this Firm --- especially in light of Trump's recent public digressions about how Quantum-AI-Tech will very soon be able to create TAILOR-MADE therapeutics, vaccines, treatments, inter alia, for any INDIVIDUAL patient suffering from all manner of Human afflictions; which is precisely what the IVVD company is attempting to do.

👍️0

B RY 3 주 전

The strong buying since feb 3rd's "Results of Operations and Financial Conditions" 8k is in 7 weeks(mar 27th/28th) the 2024 10K will reveal the details from monday's much improved financial outlook. It will be highly anticipated reading and good reason for strong price increases leading up to it and beyond. This company much needed the turn around it's experiencing that took years in the making. Good luck to your long investments aside from the fun we have day trading most stocks. I think I'll unload a couple of my other long holds that are currently dormant. Ivvd has much more promise.

👍️0

Invest-in-America 3 주 전

IVVD: I will be surprised if there is NOT yet another PR from this Firm today, on any subject.

👍️0

Zardiw 3 주 전

#DDAmanda Video: $IVVD: Gain: +204% #1 Early Alert Stock Finder

Z

👍️0

glenn1919 3 주 전

IVVD..........................https://stockcharts.com/h-sc/ui?s=IVVD&p=W&b=5&g=0&id=p86431144783

$IVVD $3.04 flip time cash out $$$I want to thank Jim Harbaugh and the NFL for pumping some more .. This broadcast is copyrighted by NFL Productions for the private use of our audience."

IVVD LOKKS LIKE 3 BUCKS COMING

👍 1

Invest-in-America 3 주 전

IVVD: Up nearly 500% in past 5-days!! (And at TOP of following important list of all Wall Street stocks UNDER $5.00!!)
https://www.barchart.com/investing-ideas/penny-stocks?orderBy=percentChange5d&orderDir=desc

👍️0

Invest-in-America 3 주 전

RFAC: Nope!! Did you grab it?? (Was it an IPO, which wasn't on MY IPO lists?)

👍️0

tw0122 3 주 전

Did you see RFAC RFACU finally rolled out at 1205pm

👍️0

Invest-in-America 3 주 전

IVVD: I had seen that, a few hours ago. Indeed, it's NOT "The Common Cold'!!!

I recall when the (late) Rush Limbago --- life-long pal of another Right-Wing-MORON, namely, Mark R. Levin --- proclaimed a few years ago on his reprobate AM Radio show, that Covid-19 was merely, "THE COMMON COLD, IT REALLY IS!!" (Verbatim)

And then, old Rush Limbago suddenly CROAKED via the perennial Human affliction, the "COMMON NECK CANCER", as it were --- vis-a-vis his 30-years of suckin' on CIGARS!!! (Talk about "KARMIC JUSTICE"!!!) And I wonder what ELSE the late RUSH LIMBAGO was 'suckin'-on' when flyin' up in DONALD DUMBFUCK's private jet, & Air-Force-1 during Trump's first term??????

Lastly, when TRUMP, VANCE, et al., are very soon SHOT-DOWN in Trump's AIR-FORCE-2(?), I'm gonna PARTY like it's 2099!!! (Can Prince's SON please write a song about that???!!!)

👍️0

Invest-in-America 3 주 전

IVVD: It's a SOLID play, Dude.

👍️0

tw0122 3 주 전

IVVD partners with Jim Harbuagh $1.76 moving a little more

👍️0

B RY 3 주 전

Missed buying ivvd monday when I saw it around .60. No big deal. I researched it well first and bought in yesterday a little above $1 on several purchases gladly. It's now on my short and rare long hold list. Good luck Invest! I think ivvd will surpass my other long holds. A phase 3 headed for possible fda approval product, headed towards strongly possible profitability in the next 2 years, 56% inst owned. Wonderful outlook. Could hit price target much sooner imo.

👍️0

al dean 3 주 전

I bought a few more on the dip. This just spiked at $1.31 again and if lot of sellers are gone, MMs forced to let it go up more. Good luck !

👍️0

TJG 3 주 전

Some pre market profit taking... see how it holds up at 8 am when Pre Market goes into full trading mode

Steady climb, Morgan Stanley has it rated at Overweight, Tipranks has it as a Moderate buy and the PR on the Phase 1/2 is nothing but solid results..Volume is double the 10 day average according to the numbers on E*Trade Snapshoot of the stock. Throw in this mornings the PR which boasted this as its headline.

DJ Invivyd Price Target Maintained With a $10.00/Share by HC Wainwright

Good enough for me to have jumped in this morning... The gap up this AM was a big excessive and is the only thing holding it back from closing at the HOD... if it can hold the mid to upper $1.20's then tomorrow it should get much closer to that $2.00 price tag.

👍️ 1

81vette 3 주 전

In .448 ,out 1.25,on to my new play

👍️0

Invest-in-America 3 주 전

IVVD; (Almost) nothing can stop this puppy --- POSITIVE PR's, & articles, & price predictions every day here --- despite its not-so-tiny FLOAT. (But they might dump-more-shares-to-market at any moment, especially day-2 here into their huge run-up; that's always the BIG worry; but since IVVD already has a big FLOAT, it is very unlikely that they would DILUTE more; in truth, it's those LOW-FLOAT stocks which love to DILUTE when epic news has just sent their pre-existing FLOAT soaring.)

👍️ 1

al dean 3 주 전

This thing has a good recipe going now. IVVD has an old support of $2.50. I'm thinking it is reachable. Thoughts ?

👍️0

Invest-in-America 3 주 전

IVVD: $2.00+ today, EEEEEE--ZZZZZZZZZZZZZZZ as PIE!!!

👍️0

glenn1919 3 주 전

IVVD.............................https://stockcharts.com/h-sc/ui?s=IVVD&p=W&b=5&g=0&id=p86431144783

Invest-in-America 3 주 전

IVVD: Nice day --- out, & done, for nice bank!! (But this would very well hit at least $1.50 in the Post-M today.)

👍️0

Invest-in-America 3 주 전

IVVD: Slap-that-ASK --- and call it DAPHNE!!!!

👍️0

Invest-in-America 3 주 전

IVVD: THANK YOU, GEEEEEEEE-ZEUS J. KRISTOOOOOOO!!!

👍 1 🥵 1 🫨 1

Invest-in-America 3 주 전

IVVD: They had two good PR's today. And despite their large Float, this could still run-up nicely later; and it's at an attractive bargain price right now, anyway ya look at this cute little puppy. (Unfortunately, I grabbed this early today at $0.67, but still holding all. Hopefully, it hits circa $2.00 later today; that's ME, below, prayin' hard right now for some 'GODLY' intervention?? But, since I'm an ATHEIST, I never get much action in that regard, so to speak.)
https://www.manilatimes.net/2025/02/03/tmt-newswire/globenewswire/invivyd-announces-preliminary-fourth-quarter-2024-financial-results-strong-revenue-growth-and-reiterates-goal-of-near-term-profitability/2048771
https://finance.yahoo.com/news/invivyd-announces-positive-phase-1-120000411.html

👍️0

81vette 3 주 전

Shares to borrow nearing zero,this could explode

👍️ 1 🚀 1

green maschine 3 주 전

Price target $3.55 - $10
https://finance.yahoo.com/news/invivyd-announces-positive-phase-1-120000411.html

👍️0

green maschine 3 주 전

https://www.manilatimes.net/2025/02/03/tmt-newswire/globenewswire/invivyd-announces-preliminary-fourth-quarter-2024-financial-results-strong-revenue-growth-and-reiterates-goal-of-near-term-profitability/2048771

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Invivyd Inc (IVVD)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

IVVD 뉴스

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Form 8-K - Current report

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Form 8-K - Current report

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

IVVD Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Invivyd Inc (IVVD) 뉴스

Invivyd Inc (IVVD)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

IVVD 뉴스

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Form 8-K - Current report

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Form 8-K - Current report

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

IVVD Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거